Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35184 | 1.00 | CYP2C19 (0.55) | CYP2C19PSIP1F2PRSS1PRSS2 | |
| SCHEMBL4248338 | 0.88 | CYP2C19 (0.55) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27961684 | 0.87 | PSIP1 (0.52) | PSIP1ALDH1A1LMNA | |
| SCHEMBL11311538 | 0.85 | CYP2C19 (0.49) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4416606 | 0.84 | ALDH1A1 (0.56) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29503157 | 0.84 | GAA (0.53) | PSIP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL11196949 | 0.84 | GAA (0.53) | PSIP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL20306074 | 0.84 | PSIP1 (0.48) | PSIP1CA1CA2ALDH1A1LMNA | |
| SCHEMBL29245371 | 0.84 | F2 (0.57) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL19071740 | 0.84 | CYP2C19 (0.54) | CYP2C19F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.